Document Detail

Response to gefitinib in pericardial effusion due to lung cancer.
MedLine Citation:
PMID:  14965177     Owner:  NLM     Status:  MEDLINE    
We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.
Norihiro Kikuchi; Hiroaki Satoh; Takahide Kodama; Norihiro Haraguchi; Kiyohisa Sekizawa
Related Documents :
21464017 - Anticoagulant acquis anti-facteur v : à propos d'un cas et revue de la littérature.
21400537 - Type a aortic intramural hematoma: clinical features and outcomes in chinese patients.
9973157 - A study of the frequency of pericardial and pleural effusions in scleroderma.
21334847 - Therapy of polymyositis and dermatomyositis.
16151877 - Size matters -- patient organisations exaggerate prevalence numbers.
6657017 - Evaluation of level of consciousness by the glasgow coma scale in children with reye's ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové     Volume:  46     ISSN:  1211-4286     ISO Abbreviation:  Acta Medica (Hradec Kralove)     Publication Date:  2003  
Date Detail:
Created Date:  2004-02-13     Completed Date:  2004-03-29     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9705947     Medline TA:  Acta Medica (Hradec Kralove)     Country:  Czech Republic    
Other Details:
Languages:  eng     Pagination:  215-6     Citation Subset:  IM    
University of Tsukuba, Institute of Clinical Medicine: Division of Respiratory Medicine, Tsukuba-city, Ibaraki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / complications,  drug therapy*
Antineoplastic Agents / therapeutic use*
Epidermal Growth Factor / antagonists & inhibitors*
Lung Neoplasms / complications,  drug therapy*
Pericardial Effusion / diagnosis,  etiology*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Quinazolines / therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Quinazolines; 62229-50-9/Epidermal Growth Factor; EC Kinases; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary non-Hodgkin lymphoma of skeletal muscle coexistence with cutaneous infiltration.
Next Document:  Practical protocols for the prevention of dental disease in community settings for people with speci...